FDA Keeps Generic Pathway Open for Protamine Sulfate and Other Drugs
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The FDA has decided that protamine sulfate injection and other listed drug products were not pulled from the market because of safety or effectiveness problems. That means these products can still serve as reference drugs for generic applications. The practical impact is mainly for generic drug companies, pharmacies, hospitals, and patients who rely on continued access to equivalent medicines. FDA can keep approving generic versions that refer to these products, as long as applicants meet the usual approval requirements.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- FDA determined that the listed drugs were not withdrawn for safety or effectiveness reasons
- Generic drug applications may continue to reference these products
- FDA will not start proceedings to withdraw approval of ANDAs that rely on these listed drugs
Obligations
What this law requires
ANDA applicants seeking approval for a generic version of a listed drug must demonstrate that the generic product has the same active ingredient(s), dosage form, route of administration, strength, conditions of use, and, except where permitted, labeling as the listed drug.
ANDA applicants must demonstrate that the proposed generic drug product is bioequivalent to the listed drug referenced in the application.